 |
|
MET tyrosine kinase inhibitor PF-02341066
An orally bioavailable agent belonging to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-02341066 inhibits the membrane receptor MET and activation of the MET signaling pathway, which may block tumor cell growth, migration and invasion, and tumor angiogenesis in susceptible tumor cell populations.
Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | c-met/hepatocyte growth factor receptor tyrosine kinase inhibitor PF-02341066
c-met/HGFR tyrosine kinase inhibitor PF-02341066 | | | | Code name: | | PF-02341066 | | |
| Previous: | mesna, Mesnex, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine, MET receptor tyrosine kinase inhibitor SGX523, Met tyrosine kinase inhibitor BMS-777607 | | Next: | MET tyrosine kinase inhibitor PF-04217903, Metastat, Metastron, metformin hydrochloride, methadone hydrochloride |
|
|
